Fluor completes Cell Therapy Launch Facility for Bayer

US-based engineering and construction firm Fluor Corporation has completed construction of pharmaceutical giant Bayer’s first global Cell Therapy Launch Facility in Berkeley, California.

A new state-of-the-art biopharmaceutical development and manufacturing facility that will be used to produce cell therapies for neurological degenerative disorders, cardiovascular disease and other unmet medical needs, has been completed by Fluor. 

Fluor’s scope of work included the engineering, procurement, construction management, commissioning, qualification and validation for the facility.

Bayer’s new Global Cell Therapy Launch Facility. Photo: Bayer

“Fluor’s innovative plant layout and modularized construction approach allowed this facility to be built safely and with capital efficiency,” said Richard Meserole, president of Fluor’s Advanced Technologies & Life Sciences business line. “The project was phased to allow start-up activities to commence as needed to support production timeline.”

Fluor also completed construction of Bayer’s state-of-the-art Single Use Technology biopharmaceutical manufacturing Cell Culture Technology Center (CCTC) in 2021. The CCTC supports Bayer’s teams producing multiple biologic therapies.